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ABSTRACT
Bisphosphonates constitute a group of drugs capable of modulating bone turnover, and reduce its remodelling when an 
excessive resorption occurs. This is why they are indicated in a large group of  bone diseases like postmenopausal oste-
oporosis or osteolisis associated with breast cancer or multiple myeloma. Over the last years and due to their extensive 
use, many cases of complications associated with their use have been published. Among the most important possible 
adeverse effects are the oral ones, with the appearance of ulcerations and, especially, osteonecrosis of the jaws associated 
with this therapy. In this paper, we have analyzed the general characteristics of these drugs and their mechanisms of ac-
tion as well as the described adverse effects, especially oral and maxillofacial has been made special reference regarding 
the prevention of osteonecrosis of the jaws, hightened by cases described in medical and odontological literature. The 
preventive protocol backs up the fundamental role of the odontologist in the effective prevention of this process before, 
during and after the treatment.
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RESUMEN
Los bisfosfonatos constituyen un grupo de fármacos capaces de modular el recambio óseo y disminuir su remodelado 
cuando existe una reabsorción excesiva. Por ello están indicados en numerosas patologías óseas como la osteoporosis 
postmenopáusica o la osteolisis asociada al cáncer de mama o al mieloma múltiple. En los últimos años y a raíz de su 
utilización masiva se han ido publicando numerosos casos de complicaciones asociadas a su uso. Entre los posibles 
efectos adversos más importantes se encuentran los orales, con la aparición de ulceraciones y sobre todo los casos de 
osteonecrosis de los maxilares asociados a esta terapéutica. En esta revisión analizamos las características generales 
de estos medicamentos y su mecanismo de actuación, así como los efectos adversos descritos, especialmente los orales 
y maxilofaciales, haciendo una referencia especial sobre la prevención de la osteonecrosis de los maxilares, a la luz de 
los casos descritos en la literatura médica y odontológica. El protocolo preventivo refuerza el papel fundamental del 
odontólogo en la prevención efectiva de este proceso antes, durante y después del tratamiento.
Palabras clave: Bisfosofonatos, efectos adversos, osteonecrosis, maxilar, prevención.
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GENERAL ASPECTS
Bisphosphonates (BPP) are non metabolized analogues of 
pyrophosphate, capable of binding to the bone and inhibit 
the osteoclast function reducing bone turnover and the acti-
ve remodelation in places where excessive bone reabsorption 
occurs (1). They have been used in toothpaste as antiplaque 
and in diagnostic tests as a conveyor of Tc 99 (2).
The first BPP introduced was etidronate with low power and 
with a tendency to produce osteomalacia (3). Searching for 
more powerful compounds and without adverse effects, the 
second (alendronate, pamidronate, ibandronate, tiludronate) 
and the third generation BPP  risedronate, zoledronic acid, 
minodronate) have been developed. 
Few changes in the structure of  BPP modify their phy-
sicochemical, biological, therapeutic and toxicological 
properties (4). 
The structure of  BPP (Figure 1), shows two phosphate 
groups binding to a carbon atom (P-C-P), that to a certain 
extent is responsible for their low bioavailability. Like pyro-
phosphates, BPP bind strongly to hidroxiapatite, explaining 
their pharmacological actions in the bone (5). R1 radicals 
influence in their affinity, therefore, OH groups increase the 
fixation, while Cl groups decrease it. This would explain 
why BPP with OH groups (alendronate, pamidronate…) 
bind more than clodronate (6).
BPP are released when there is bone reabsorption that would 
explain their long half-life (7). This release is multiphasic, 
and in the case of alendronate is 10.5 years. This fact would 
explain their persistent long term effect in the bone (8).
MECHANISM OF ACTION
BPP inhibit bone reabsorption by reducing osteoclast 
reabsorptive activity (9), promoting their apoptosis (10), 
avoiding their formation from hematopoyetic precursors 
(11) or affecting osteoblasts (12).
Once inside the osteoclast, R2 chain determines the power 
and efficacy of the drug. In the case of clodronate (Cl in R2) 
and etidronate (CH3 in R2), they act through the metabo-
lization to toxic analogues of ATP that induce osteoclastic 
apoptosis (13).
Different studies (14,15), have proved the role of FPP-syn-
thase like molecular target of  nitrogen-containing BPP. 
These drugs induce osteoclast apoptosis by the inhibition 
of cholesterol biosynthesis and the mevalonate pathway, 
due to the inhibition of the synthesis of farnesilpirophos-
phate (16-19). These disturbances affect the organization 
of cytoskeleton, vesicle traffic and the formation of the 
osteoclast brush border. BPP also have some effect on the 
osteoblasts, which is still not totally clear, reducing apoptosis 
and stimulating the secretion of inhibitors in the recruitment 
of osteoclasts (20).
It has also been said to have an antiangiogenic effect on 
BPP by the inhibition of endothelial cells, reducing their 
proliferation and inducing apoptosis (21).
THERAPEUTIC INDICATIONS
The indications of BPP have undergone a large evolution 
since they were introduced in the treatment of some bone 
and calcium metabolic disorders (22, 23). Nowadays, the 
main indications of BPP are:
1. In postmenopausal and corticosteroid induced osteopo-
rosis. In these cases the most used BPP is alendronate, which 
precludes the appearance of pathological fractures (24).
2. In Paget’s disease, it is used to improve  bone morphology 
and reduce pain (25).
3. In hypercalcaemia of malignancy, its role is in trying to 
check hypercalcaemia, reducing pain and preventing the 
development of osteolitic lesions and fractures (26).
4. In  patients with breast and prostate cancer with bone 
metastasis, it is used to relieve pain, reduce fractures and 
hypercalcaemia (27, 28).
5. In multiple myeloma, it is indicated to reduce associated 
bone pathologies such as vertebral collapse, fractures and 
pain (29, 30).
Oral BPP are potent inhibitors of  osteoclasts, but less 
efficient in the treatment of  bone processes associated 
with malignant diseases. Therefore, they were principally 
indicated in the treatment of osteoporosis. On the other 
hand, systemic BPP are indicated in patients with metas-
tatic breast cancer, multiple myeloma, hypercalcaemia of 
malignancy, Paget’s disease and bone metastasis of solid 
tumours (prostate, lung…)
GENERAL ADVERSE EFFECTS
BPP are well tolerated in general if  they are correctly admi-
nistrated. Nevertheless, various adverse effects and compli-
cations associated with their use have been described.
In the case of oral BPP, the digestive effects are the most 
frequently described:  gastric ulcerations, oesophagitis and 
oesophago stenosis.
Isolated cases of uveitis in patients treated with alendronate 
(31, 32), pamidronate (33, 34) and recently with zoledronic 
acid (35) have been described.
The continuous administration of etidronate can produce a 
picture of osteomalacia that regresses after discontinuation 
of therapy (36, 37). Nevertheless, the most modern BPP do 
not present this adverse effect.
Some experimental models have contemplated the possibi-
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Fig. 1. Basic structure of the Bisphosphonates.
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lity that the inhibition of bone remodelation may lead to a 
reduction of  bone resistance although there is no clinical 
evidence, at least concerning the administration of oral BPP. 
In fact, even with the most powerful BPP, the remodeling 
process is completely annulled (38).
The general adverse effects of intravenous BPP are similar 
to the oral ones, and some cases of flebitis (18%) have been 
described. There are also accounts of transitory febricula, 
shivers (10-41%) and a pseudogrippal syndrome (20%) in 
the first two days (39).
There are references of hypocalcaemia, usually asymptoma-
thic, after high doses of BPP (40, 41). Nevertheless, most 
of the patients are unaffected thanks to the compensatory 
increase of parathyroid hormone (42). 
One has to be careful when high doses of intravenous BPP 
are administrated because its rapid administration can cause 
renal failure, due to the formation of a solid phase in the 
blood, which is retained in the kidney.
ORAL ADVERSE EFFECTS
There are some cases of  chronic ulcerations in the oral 
mucosa associated with the administration of aldostero-
ne in osteoporotic patients (44). These cases belonged to 
postmenopausal osteoporotic women in treatment with 
alendronate. They presented oral ulcerations in the mu-
cosa secondary to an inappropriate administration, which 
disappeared with topic corticoids. There are other cases of 
oral ulcerations generally associated with an inappropriate 
administration (45, 46). Figure 2 presents a recent case of 
a 55 year woman with ulcerations in the floor of the mouth 
associated with the alendronate administration.
In the past 4 years there have been publications describing 
numerous cases of a special form of osteonecrosis of the 
jaws (ONJ) in patients affected with myeloma or breast 
cancer and in treatment with high effectiveness BPP, es-
pecially pamidronate and zoledronic acid and more rarely 
with alendronate (47-50).
Two theories have been proposed to explain the appearance 
of ONJ. One related to the action of the BPP in bone tur-
nover, and the other to their antiangiogenic action (51). The 
main theory suggests that ONJ is caused by the cessation of 
bone remodelling and the osteoclast-inhibiting effect. BPP 
is highly concentrated in the jaws because there is a greater 
blood supply than in other bones and a faster bone turnover, 
related to their high activity and the presence of the teeth. 
This circumstance, together with the frequent appearance 
of dental pathologies, odontological treatment and the thin 
mucosa over the maxilar bone; explains why osteonecrosis 
is especially patent in these bones. 
The bone turnover maintenance is crucial to maintain bone 
viability. If osteoclast function decreases severely, osteocytes 
are not replaced and bone capillary network is not maintai-
ned, permitting the appearance of avascular bone necrosis 
(52). The breakdown of the oral mucosa, caused by a trau-
matic ulceration or surgery, causes local bone necrosis which 
progresses when healing fails. The risk of ONJ increases 
with dental manipulation and poor hygiene, because bone 
is exposed to the oral microbiota, later causing infection 
with pain, tumefaction, suppuration and progressive bone 
necrosis, which is difficult to control (53).
The other etiopatogenic theory is based on experimental 
evidence showing that most potent BPP also inhibit ca-
pillary neoangiogenesis, decreasing capillary formation 
and inhibiting endothelial growth factors (21), leading to 
avascular necrosis. However, this is not the only cause as it 
is not associated with the administration of more potent 
antiangiogenic drugs (54, 55).
There are accounts of ONJ cases associated with BPP in 
patients who have been on medication for years, and even 
for a few weeks (53). However, a study of multiple myeloma 
patients showed that ONJ risk is time-dependent and is 
significant only after 12 or 36 months after (56). 
PREVENTION OF BPP ASSOCIATED OSTEO-
NECROSIS OF THE JAWS
As in any prophylactic approach, the preventative measures 
of osteonecrosis of the jaws is introduced before initiating 
BPP therapy.
a.- Measures before initiating BPP therapy
As soon as the oncologist or other specialists consider the ad-
ministration of BPP necessary, the patient should be referred 
to a dentist for an urgent oral examination (57), consisting of 
a complete clinical and radiographic exploration. 
Oral treatment is aimed at eliminating infections and the 
need for invasive dental procedures in the near future; so 
preventive therapy should be aggressive and should include: 
tooth removal, periodontal surgery, root canal treatment, 
tooth decay control, dental restorations and prothesis if nee-
ded. These patients are not candidates for dental implants 
because of the risk elements involved (51). A month before 
initiating BPP therapy, removal of large mandibular tori or 
palatal tori with thin overlying mucosa, is recommended to 
avoid the risk of ulcerations.
Fig. 2. Ulcerations in the floor of the mouth  following alendro-
nate administration.
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Patients with no cardiac disease do not require prophylactic 
antibiotic coverage for non invasive procedures but there is a 
need for an invasive procedure; in this case, the chosen drug 
is penicillin and its derivatives. For individuals with peni-
cillin allergy, a combination therapy using quinolones and 
metronidazole have proven efficient. Clindamycin alone is 
not recommended because it is ineffective against actinomy-
ces, Eikenella corrodens, and similar species that frequently 
colonize the exposed bone in the oral cavity (51).
If  the patient requires only non invasive dental care BPP 
therapy is not delayed. But if  the patient requires invasive 
procedures, BPP therapy should be deferred for a month 
to allow bone recovery and good healing. A surveillance 
schedule every 4 months with plaque control and strict 
hygienic measures is recommended. 
b.- Measures during BPP therapy
The dentist should carefully examine the oral cavity in the 
search for the presence of  bone expositions in the most 
commonly affected areas, such as the posterior and lingual 
area of the mandible. A complete radiographic examina-
tion should be carried out to look for signs of osteolysis, 
osteosclerosis, widened periodontal spaces and furcation 
affection. 
A careful dental cleaning and preventive use of fluor and 
clorhexidine should be considered as well as strict hygienic 
measures (51).
All the needed procedures to conserve the teeth and avoid 
the appearance of infections should be done as soon as pos-
sible. If  the tooth is not restorable, root canal treatment and 
amputation of the crown are preferable to extraction. Root 
canal treatment should be carried out with minimum trauma 
to the marginal and apical periodontal tissues (58).   
In relation to periodontal disease, teeth will only be removed 
when they have 3 or more mobility grade or an associated 
periodontal abscess. In these situations, adequate antibiotic 
treatment is imperative, as previously indicated (51).   
Surgery procedures are contraindicated. Nevertheless, in 
patients that need surgery, BPP withdrawal is recommended 
in the case of a bad recovery. However, it is not certain that 
BPP withdrawal will prevent the appearance of ONJ, due 
to their half-life (59).
When oral surgery procedure is needed in a patient with BPP 
therapy, some special precautions should be taken as for 
instance, absolutely aseptic procedures, atraumatic surgery 
and achieving a first intention closing if  possible (60). 
If prosthesis is needed, it should be preferably fixed and well 
carried out, to avoid if possible the appearance of secondary 
traumatic ulcerations.
In patients in treatment with BPP it is recommended to 
engage in a continuous surveillance schedule every 3 or 4 
months with plaque control and strict hygienic measures. 
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